Lv1
82 积分 2023-07-14 加入
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy
3天前
已完结
CAR T-cell therapies in China: rapid evolution and a bright future
6天前
已完结
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
11天前
已完结
Landmark perspective: Nitrogen mustard therapy
11天前
已关闭
Radiation therapy of localized non-Hodgkin's lymphoma
11天前
已关闭
A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
20天前
已完结
HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study
20天前
已完结
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
20天前
已完结
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study
26天前
已完结
Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma
26天前
已关闭
皖公网安备34019202002308
